Stockwatch: United Cannabis Corporation Files Utility and PCT Patent Applications for Unique Combinations of Pharmaceutically Active Cannabinoids

http://www.stockwatch.com/News/Item.aspx?bid=U-prLA45600-U:CNAB-20151102&symbol=CNAB&region=UDENVER, Nov. 2, 2015
/PRNewswire/ -- United Cannabis Corporation (OTCQB: CNAB) (the
"Company" or "United Cannabis") today announced that it moved its
provisional patent application to the next phase by filing a utility
patent application related to the unique combinations of
pharmaceutically active cannabinoids used to treat disorders of the
nervous system, immune system and cancer with the U.S. Patent and
Trademark Office.
The company has also filed a PCT application for pursuing international patents.
United
Cannabis' research team has identified unique ratios and specifications
of cannabinoids that may be used to target the underlying mechanisms of
disorders such as insomnia, anxiety, neuropathy, Crohns disease,
seizures, and cancer.
The patent application identifies a matrix
system for categorizing CBD & THC rich strains with specific terpene
profiles into accurately dosed delivery methods for both inactive and
active cannabinoids. The patent application includes a wide range of
extraction methods including a plant fat delivery system of the
medicine. The delivery methods include: capsule, sublingual, and
topical.
Tony Verzura, United
Cannabis' Chief Technology Officer, commented, "We continue our march
forward into the future of cannabis-based medicine. We have made great
progress with the optimum delivery methods and combinations of
cannabinoids that provide the greatest benefit to the patient. This next
step in our patent application process brings us closer to providing
cannabis-based solutions for a broad range of ailments."
2015-11-02 16:17 ET - News Release

\t\tPatent Application Relates to Proprietary Formulations Targeting Disorders of the Nervous System, Immune System and Cancer

DENVER, Nov. 2, 2015
/PRNewswire/ -- United Cannabis Corporation (OTCQB: CNAB) (the
"Company" or "United Cannabis") today announced that it moved its
provisional patent application to the next phase by filing a utility
patent application related to the unique combinations of
pharmaceutically active cannabinoids used to treat disorders of the
nervous system, immune system and cancer with the U.S. Patent and
Trademark Office.
The company has also filed a PCT application for pursuing international patents.
United
Cannabis' research team has identified unique ratios and specifications
of cannabinoids that may be used to target the underlying mechanisms of
disorders such as insomnia, anxiety, neuropathy, Crohns disease,
seizures, and cancer.
The patent application identifies a matrix
system for categorizing CBD & THC rich strains with specific terpene
profiles into accurately dosed delivery methods for both inactive and
active cannabinoids. The patent application includes a wide range of
extraction methods including a plant fat delivery system of the
medicine. The delivery methods include: capsule, sublingual, and
topical.
Tony Verzura, United
Cannabis' Chief Technology Officer, commented, "We continue our march
forward into the future of cannabis-based medicine. We have made great
progress with the optimum delivery methods and combinations of
cannabinoids that provide the greatest benefit to the patient. This next
step in our patent application process brings us closer to providing
cannabis-based solutions for a broad range of ailments."
Earnest Blackmon,
United Cannabis' Chief Executive Officer, commented, "We are excited to
continue working on developing and improving products as well as
patient support services through our Advanced Cannabinoid Therapy
program (A.C.T. Now Program). We look forward to fostering long term
relationships with qualified licensed centers in states with compliant
regulatory structures."
About United Cannabis Corporation
United
Cannabis Corporation was formed to advance the use of cannabinoids in
medicine through research, product development and education. The
Company is dedicated to improving the lives of patients through the
creation of products using only the highest quality genetics, purest
extractions and most effective protocols possible. The Company's A.C.T.
Now Program and patent-pending Prana Bio Nutrient Medicinals provide a
comprehensive solution designed to enable physicians and patients to
design, implement and monitor effective therapy protocols.
For further information, please visit www.unitedcannabis.us
Forward-Looking Statements
Certain
statements in this news release may contain forward-looking information
within the meaning of Rule 175 under the Securities Act of 1933, and
are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and
are subject to the safe harbor created by those rules. All statements,
other than statements of fact, included in this release, including,
without limitation, statements regarding potential future plans and
objectives of the company, are forward-looking statements that involve
risks and uncertainties. There can be no assurance that such statements
will prove to be accurate and other results and further events could
differ materially from those anticipated in such statements. Future
events and actual results could differ materially from those set forth
in, contemplated by, or underlying the forward-looking statements.
Contact:

UCANN Staff

303-386-732

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/united-can...
SOURCE United Cannabis Corporation

\t\t© 2015 Canjex Publishing Ltd. All rights reserved.